News

  • 31 October 2018

    Axonics Modulation Technologies, Inc. (“Axonics”), a medical technology company focused on the design, development and commercialization of innovative and minimally invasive sacral neuromodulation (“SNM”) solutions for the treatment of overactive bladder (“OAB”), fecal incontinence (“FI”), and urinary retention (“UR”), today announced the pricing of its initial public offering of 8,000,000 shares of common stock at an initial public offering price of $15.00 per share, before underwriting discounts and commissions. Axonics has also granted the underwriters a 30-day option to purchase an additional 1,200,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Axonics.

  • 29 October 2018

    Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies (the “Company”), announces today that the independent Safety Monitoring Board (SMB) for its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC) held its third pre-planned data review meeting and recommended the continuation of the Company’s trial without protocol amendment. 

  • 23 October 2018

    The board of directors of InDex Pharmaceuticals Holding AB (publ) (the “Company” or “InDex”) has, with support from the authorization granted by the annual general meeting on May 24, 2018, resolved on a directed share issue of 6,252,842 shares to a small group of investors. The subscription price is SEK 6.02 per share, corresponding to a discount in line with market conditions of 7.7 percent to the 5-day volume weighted average price and 1.3 percent to today’s closing price. InDex will receive proceeds of approximately SEK 37.5 million after transaction related costs for legal services and costs for registration and practical management.

  • 18 October 2018

    Sonendo®, the developer of the GentleWave® System, today announced that it has acquired TDO (The Digital Office™) Software.

  • 15 October 2018

    Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that an abstract with preclinical data that demonstrate the activity of GKT831, the Company’s lead product candidate, in reversing fibrosis in a MDR2 KO mouse model will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (the Liver Meeting®), which will take place in San Francisco, November 9-13, 2018. The poster will be presented on Saturday, November 10 (2:00 pm–7:30 pm; Presenters Available: 5:30 pm–7:30 pm).